Peptide-Based Cancer Immunotherapy: Neoantigen Vaccines and Checkpoint Inhibitor Synergies

Background

Peptide-based cancer immunotherapy represents one of the most active frontiers in oncology research, leveraging the immune system's ability to recognize and destroy tumor cells expressing abnormal proteins. Two major peptide-based strategies have converged in recent years: personalized neoantigen vaccines, which train the immune system to target tumor-specific mutations, and peptide-derived checkpoint inhibitors that modulate immune regulation. Neoantigens arise from somatic mutations unique to an individual's tumor and are not subject to central tolerance, making them attractive targets for therapeutic vaccination. When combined with immune checkpoint blockade — particularly anti-PD-1 and anti-PD-L1 antibodies — neoantigen vaccines may amplify anti-tumor immune responses beyond what either approach achieves alone.

Methods

The landmark clinical study by Ott and colleagues (2017), published in Nature, conducted a phase I trial of a personalized multi-peptide neoantigen vaccine in six patients with previously treated high-risk melanoma. Each patient received up to 20 synthetic long peptides targeting predicted neoantigens, adjuvanted with poly-ICLC. Subsequent trials have expanded this approach: a phase I/II study evaluated a personalized DNA plasmid neoantigen vaccine (GNOS-PV02) encoding up to 40 neoantigens co-administered with plasmid interleukin-12 and pembrolizumab in advanced hepatocellular carcinoma. Multiple active clinical trials are investigating neoantigen peptide vaccines combined with PD-1 inhibitors and radiotherapy in advanced non-small cell lung cancer (NSCLC) patients who have progressed on first- or second-line therapy.

Key Findings

In the Ott et al. melanoma trial, all six vaccinated patients generated robust CD4+ and CD8+ T cell responses against their personal neoantigen peptides. Four of six patients showed no disease recurrence at 25 months post-vaccination. The two patients who experienced recurrence subsequently responded to anti-PD-1 therapy (pembrolizumab), achieving complete tumor regression — suggesting that the vaccine-primed immune response was further activated by checkpoint blockade.

The hepatocellular carcinoma phase I/II trial demonstrated that personalized neoantigen vaccination combined with pembrolizumab was feasible, safe, and immunogenic in patients with advanced disease. Neoantigen-specific T cell responses were detected in the majority of evaluable patients.

A comprehensive review of neoantigen cancer vaccines found that early clinical trials consistently demonstrate safety, tolerability, and immunogenicity across multiple tumor types. However, objective clinical response rates as monotherapy remain modest, providing the rationale for combination approaches with checkpoint inhibitors, radiation, and other immunomodulatory agents.

Implications

Peptide-based neoantigen vaccines represent a highly personalized approach to cancer treatment that may complement existing immunotherapy strategies. The consistent demonstration of neoantigen-specific T cell activation across trials supports the biological premise that tumor-specific peptide vaccination can meaningfully engage the adaptive immune system. The synergy observed between neoantigen vaccines and PD-1 checkpoint blockade suggests that optimal clinical benefit may require combination therapy to overcome the immunosuppressive tumor microenvironment.

Limitations

Neoantigen vaccine development faces several practical challenges. The manufacturing timeline — from tumor sequencing to neoantigen prediction, peptide synthesis, and quality control — typically requires 8 to 12 weeks, limiting applicability in rapidly progressive disease. Neoantigen prediction algorithms remain imperfect, with only a fraction of predicted epitopes proving immunogenic. Clinical trials to date have enrolled small numbers of patients, and no phase III randomized trials have yet reported results. The cost of fully personalized vaccine manufacturing at scale remains a significant barrier to broad clinical adoption.